| Literature DB >> 31236392 |
Jun-Liang Yuan1, Wei-Xue Wang2, Wen-Li Hu3.
Abstract
BACKGROUND: Syphilitic myelitis caused by Treponema pallidum is an extremely rare disease. However, symptomatic neurosyphilis, especially syphilitic myelitis, and its clinical features have been infrequently reported. Only a few cases of syphilitic myelitis have been documented. To the best of our knowledge, there are only 19 reported cases of syphilitic myelitis. However, the clinical features of syphilitic myelitis with longitudinally extensive myelopathy have been still not clear. AIM: To explore the clinical features of syphilitic myelitis with longitudinally extensive myelopathy on spinal magnetic resonance imaging (MRI).Entities:
Keywords: Human immunodeficiency virus; Neurosyphilis; Syphilitic meningomyelitis; Syphilitic myelitis
Year: 2019 PMID: 31236392 PMCID: PMC6580337 DOI: 10.12998/wjcc.v7.i11.1282
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Spinal cord magnetic resonance imaging showed abnormal longitudinally extensive T2 weighted hyperintensities involving the posterior columns from C7 through T6, with "flip-flop sign" on cervical spinal magnetic resonance imaging.
Figure 2Spinal cord magnetic resonance imaging showed abnormal longitudinally extensive T2 weighted hyperintensities involving the posterior columns from C7 through T6, with "flip-flop sign" on cervical spinal magnetic resonance imaging. Focal enhancement was observed in the dorsal aspect of the thoracic cord on T1- weighted gadolinium-enhanced images at T3-T4 level.
Figure 3Abnormal hyperintensities on spinal magnetic resonance imaging also resolved at three-month follow-up.
Clinical features of syphilitic myelitis with longitudinally extensive myelopathy
| Ref. | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | [ | Our case |
| Age | 46 | 31 | 17 | 29 | 17 | 28 | 63 | 57 | 36 | 46 | 63 | 38 | 32 | 35 | 30 | 49 | 41 | 36 | 49 | 25 |
| Gender | M | M | F | F | M | M | M | F | M | M | M | M | M | M | F | M | M | M | M | M |
| Clinical features | Gait, sensory disturbance, dysuria | Sensory disturbance, paraparesis | Paraparesis, sensory disturbance, urinary retention | Numbness, sensory disturbance, paraparesis | Paraplegia | Chorioretinitis, spastic paraparesis | Sensory deficit, weakness, urinary disturbance | Paraplegia, urinary retention | Pain, paraparesis | Numbness, pain | Pain, weakness | Pain, weakness, numbness, retained urination | Tingling, numbness | Acute transverse myelitis | Acute transverse myelitis | Gait, paresthesia, loss of pain and temperature, urinary retention | Unconscious, numbness | Paresthesia, ascending paresis in inferior limbs | Loss of bilateral strength, sensory impairment | Sensory disturbance, numbness |
| Duration | 2 wk | 10 d | 8 d | 9 mo | NA | 180 d | 60 d | 3 d | 4 mo | 7 d | 12 d | 4 mo | 4 mo | 2 wk | 1 mo | 2 wk | NA | NA | NA | 7 d |
| High risk behavior | NA | + | + | + | NA | + | NA | NA | NA | + | NA | + | + | + | NA | + | + | NA | NA | + |
| HIV infection | NA | NA | NA | NA | + | - | - | - | - | - | - | - | - | - | - | + | + | + | + | - |
| Blood VDRL | NA | 1:640 | 1:4 | 1:4 | 1:16 | NA | NA | 1:8 | Reactive | 1:64 | 1:16 | RPR (1:128) | 1:16 | Reactive | Non-reactive | Reactive | RPR+ | NA | NA | TRUST+ RPR (1:16) |
| Blood TPHA | NA | >1:20480 | Reactive | Reactive | FTA-ABS (1:6400) | NA | NA | FTA (3+) TPHA (2+) | 1:5120 | 1:81920 | Reactive | 4+ | 1:160 | 1:5120 | 1:1280 | 1:2560 | + | NA | NA | + |
| CSF protein (mg/dL) | High | 94 | 52 | 54 | 106 | 94 | 200 | Normal | 243 | 72 | 91.70 | 88 | 40 | 123 | 57 | 79 | NA | NA | NA | 148 |
| CSF cells (/μL) | Pleocytosis | 120 | 75 | 20 | 180 | 120 | 498 | Pleocytosis | 346 | 113 | 303 | 18 | 40 | 115 | 170 | 202 | NA | NA | NA | 110 |
| CSF VDRL | Reactive | 1:80 | Non-reactive | Non-reactive | NA | + | + | 1:2 | NA | NA | Reactive | 1:16 | + | Reactive | Reactive | NA | + | NA | NA | NA |
| CSF TPHA | Reactive | 1:5120 | Non-reactive | Reactive | FTA-ABS (1:100) | TPHA+ | NA | NA | FTA-ABS (1:320), TPHA (1:640) | NA | NA | NA | NA | NA | NA | + | NA | NA | NA | NA |
| Spinal MRI | High T2 intensity, abnormal Gd-DTPA enhanced | T3/4 wedge-shaped Gd-DTPA enhanced high intensity, swollen spinal cord | Below the C4 diffuse high signal, candle guttering appearance | T1-T11 abnormal signal, flip-flop sign | NA | T6-T8 | LETM, Gadolinium enhancement | Extensive central high T2 signal, enhancement of the dorsal T8-T9 | Diffuse high T2 signal, flip-flop sign | T2-T6 high signal, focal Gd-DTPA enhancement | T6-T11 high signal, focal Gd-DTPA enhancement | Ventral part on the level of T6–T7 | T5-T12 hyperintense signals | Spine-cord edema from D4 to conus medullaris | Spine-cord edema from cervicodorsal up to conus | High-intensity lesions from C4 to T6 | Spinal cord edema from C3-T1 | Signal impairment in the spinal cord (T2-T12) | Diffuse hypersignal at several levels | Longitudinally extensive T2 hyperintensities involving C7 to T6 |
| Treatment | Antibiotic therapy | Penicillin, prednisolone | Penicillin | Penicillin, cephalosporins | Penicillin | Penicillin, dexamethasone | Penicillin, dexamethasone | Antibiotic therapy | Penicillin | Penicillin, methylprednisolone | Ceftriaxone, methylprednisolone | Penicillin, prednisolone | Penicillin | Procaine penicillin, Methyl prednisole | Procaine penicillin, donapezil | Penicillin potassium, methylprednisolone | Penicillin | Penicillin | Penicillin | Penicillin |
| Follow-up duration | NA | 16 d | 14 d | 1 mo | NA | NA | 2 yr | 4 wk | 28 d | 21 d | 30 d | NA | 14 d | 6 mo | Lost | 2 wk | 1 wk | NA | NA | 3 mo |
| Status | Improved | Improved | Complete remission | Improved | Spasticity | NA | Improved | Non improved | Improved | Improved | Improved | Positive effect | NA | Same | NA | Improved | Improved | Complete improvement | Partial improvement | Improved |
| Repeat CSF finding | NA | TPHA (1:2560), VDRL (1:40) | Cells 9/μL, protein 38 mg/dL | NA | Non-reactive | NA | NA | NA | Reduced | N | Cells 34/μL, protein 45.4mg/dL | NA | NA | NA | NA | NA | MA | NA | NA | Cells 24/μL, protein 65 mg/dL, TPPA +, TRUST 1:1. |
| Repeat blood finding | NA | TPHA (1:10240), VDRL (1:160) | NA | NA | NA | NA | NA | NA | NA | VDRL (1:16) | RPR (1:4) | RPR (1:64) | NA | NA | NA | NA | NA | NA | NA | TPPA (+), TRUST (1:8) |
| Repeat MRI finding | Disappearance of intramedullary high intensity areas | Reduction in the intensity of lesions | Reduction in the intensity of lesions | Reduction in the intensity of lesions | NA | NA | NA | Disappearance of the high signal lesion on T2-weighted images | Gadolinium enhancement disappeared, the high signal intensity diminished | NA | Reduction in the intensity of lesions | NA | NA | NA | NA | Reduction in the size of the cervical and thoracic cord lesions | NA | NA | NA | Dissolved with three months' follow up |
M: Male; F: Female; NA: Not applicable; VDRL: Venereal disease research laboratory; TPHA: Treponema pallidum hemagglutination assay; LETM: Longitudinally extensive transverse myelitis; RPR: Rapid plasma regain; TRUST: Toluidine red unheated serum test; T: Thoracic; C: Cervical; CSF: Cerebrospinal fluid; HIV: Human immunodeficiency virus; NA: Not applicable; FTA-ABS: Fluorescent treponemal antibody-absorption; +: Positive.